Condensed Consolidated Statements of Comprehensive Loss - USD ($)	3 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Revenues:
Product sales	$ 597,514	$ 581,248
License fee and other revenues	15,107	10,825
Research and development	129,185	138,805
Total revenues	741,806	730,878
Costs and Expenses:
Costs of goods sold	255,105	58,264
Research and development	14,525,864	12,913,130
Sales and marketing	215,856	143,521
General and administrative	691,584	1,724,294
Total costs and expenses	15,688,409	14,839,209
Operating loss	(14,946,603)	(14,108,331)
Interest expense	(1,369,955)	(1,369,955)
Interest and other income, net	85,206	91,958
Foreign currency transaction gain (loss), net	2,459	(10,461)
Loss before income tax	(16,228,893)	(15,396,789)
Income tax expense		(19,250)
Net loss	(16,228,893)	(15,416,039)
Less: Net loss attributable to noncontrolling interest	(31,045)	(22,217)
Net loss attributable to Immunomedics, Inc. stockholders	$ (16,197,848)	$ (15,393,822)
Loss per common share attributable to Immunomedics, Inc. stockholders (basic and diluted):	$ (0.17)	$ (0.16)
Weighted average shares used to calculate loss per common share, (basic and diluted)	95,883,729	94,595,826
Other comprehensive (loss) income, net of tax:
Foreign currency translation adjustments	$ 37,108	$ 17,468
Unrealized (loss) gain on securities available for sale	(32,609)	33,697
Other comprehensive income	4,499	51,165
Comprehensive loss	(16,224,394)	(15,364,874)
Less comprehensive loss attributable to noncontrolling interest	(31,045)	(22,217)
Comprehensive loss attributable to Immunomedics, Inc. stockholders	$ (16,193,349)	$ (15,342,657)